Contrast Media Injectors Market Worth $1.9 Billion By 2025
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- The report Contrast Media Injectors Market size is estimated to be USD 1.3 billion in 2020 and projected to reach USD 1.9 billion by 2025, at a CAGR of 7.4%.
Factors such as the growing prevalence of cancer and CVD; a large number of approvals for contrast agents; and increasing investments, funds, and grants by government organizations are driving the growth of the contrast media injectors market. However, the high cost of contrast media injectors and consumables & accessories is restraining the growth of the market to a certain extent.
The report Contrast Media Injectors Market size is estimated to be USD 1.3 billion in 2020 and projected to reach USD 1.9 billion by 2025, at a CAGR of 7.4% between 2020 and 2025
Ask for PDF Brochure: - Contrast Media Injectors Market
The consumables segment accounted for the largest share of the contrast media injection market, by type, in 2019.
Based on the product, the contrast media injectors market is segmented into injector systems, consumables, and accessories. The injector systems market is segmented further into CT injectors, MRI injectors, Angiography injectors. The consumables segment is segmented further into syringes, tubes, other consumables. In 2019, the consumables segment accounted for the largest share of the contrast media injectors market. The large share of this segment can be attributed to the growing requirement of consumables to maintain safety and hygienic conditions during diagnostic procedures. These consumables need to be re-purchased for every new procedure, as opposed to instruments, thus driving its demand.
The interventional cardiology segment to register the highest CAGR in the contrast media injector market during the forecast period.
Based on application, the contrast media injectors market is segmented into radiology, interventional radiology, and interventional cardiology. In 2019, the interventional cardiology segment had the highest growth rate of the contrast media injectors market. The rising prevalence of CVD is driving the growth of this application segment.
The hospital segment will continue to dominate the contrast media injector end-user market during the forecast period
Based on end-user, the contrast media injectors market is segmented into hospitals and diagnostic imaging centers. The hospital segment commanded the highest growth rate of the global contrast media injectors market in 2019. The high growth rate of this segment can be attributed to the rising number of diagnostic imaging procedures performed in hospitals and the growing inclination of hospitals towards the automation & digitization of radiology patient workflow.
North America will continue to dominate the contrast media injector market during the forecast period
Geographically, North America dominated the contrast media injector market in 2019, while Asia Pacific is expected to register the highest CAGR during the forecast period. The large share of North America is attributed to the increasing number of diagnostic imaging units & examinations, rising aging population & corresponding disease conditions in the US, significant focus & government investments in the medical imaging arena, and increasing research activities in Canada.
Request for Sample Pages: - Contrast Media Injectors Market
Top Key Players:-
Major players operating in the Contrast Media Injector market include Bayer Ag (Germany), Bracco Imaging S.P.A (OTCPK:ITALY), Guerbet Group (France), Ulrich GmbH & Co. KG (Germany), Nemoto Kyorindo Co., Ltd. (Japan), Sino Medical-Device Technology Co., Ltd. (Sinomdt) (CHINA), APOLLO RT Co. Ltd. (Hongkong), Shenzhen Anke High-Tech Co. Ltd. (CHINA), Shenzen Seacrown Electromechanical Co. Ltd. (CHINA), and Medtron AG (Germany).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.